[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576695":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants treated with lisocabtagene maraleucel",null,[12],"Biological: Lisocabtagene maraleucel",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Lisocabtagene maraleucel","According to the United States Prescribing Information",[9],[20],{"name":21,"affiliation":21,"role":22},"Bristol-Myers Squibb","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"Center for International Blood and Marrow Transplant Research (CIBMTR)","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-87.90647,43.0389,{"lat":44,"lon":43},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100576695","a-study-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-treated-with-lisocabtagene-maraleucel-in-the-post-marketing-setting-100576695",false,"NCT06788639","A Study of Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma in the Post-Marketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion\n* Patients treated with non-conforming CAR T-cell product","ALL","18 Years",{"count":58,"type":59},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities",[63,64],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[63,64],"2025-02-21",{"date":68,"type":69},"2025-02-24","ACTUAL",{"date":71,"type":69},"2025-02-04",{"date":73,"type":59},"2044-06-30",{"name":5,"class":6},1]